Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Takeda obtains approval of Adcetris for treatment of malignant lymphoma in Japan

Jan. 17, 2014

Immunomedics begins phase III trial of yttrium Y 90 clivatuzumab tetraxetan

Jan. 16, 2014

Synthon Biopharmaceuticals prepares for phase I study of SYD-985

Jan. 16, 2014

Merck & Co. begins rolling submission of BLA for MK-3475

Jan. 14, 2014

Monoclonal antibody Hu3F8 receives FDA orphan drug status for osteosarcoma

Jan. 14, 2014

EMA accepts Biovest's MAA for BiovaxID

Jan. 14, 2014

GlaxoSmithKline presents a novel antibody-drug conjugate for the treatment of multiple myeloma

Jan. 13, 2014

Researchers present phase I results for 225Ac-lintuzumab in older patients with AML

Jan. 13, 2014

IGN-532 shows preclinical efficacy in xenograft models of AML

Jan. 10, 2014

Galena enrolls first patient in phase II trial of GALE-301 cancer immunotherapy in ovarian cancer

Jan. 9, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...